Mantle Cell Lymphoma

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

Grzegorz S. Nowakowski, MD, an assistant professor of Medicine at Mayo Clinic, discusses the status of emerging agents moving through the pipeline of mantle cell lymphoma.

John P. Leonard, MD, professor of medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the maintenance strategy of rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

Grzegorz S. Nowakowski, MD, discusses ongoing efforts to determine prognostic factors of mantle cell lymphoma and what other challenges lie ahead.

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian, discusses preferences patients have for their treatment of mantle cell lymphoma (MCL).

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses some of the recent therapeutic advancements that have been reported in the field of mantle cell lymphoma (MCL).

Grzegorz S. Nowakowski, MD, discusses the ever-changing landscape of mantle cell lymphoma, the intriguing combinations being studied, and the promise that immunotherapy could hold.

Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.

Grzegorz Nowakowski, MD, assistant professor of medicine, Mayo Clinic, discusses the evolving treatment paradigm of mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma (MCL).

Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the challenges that exist in the future of treatment for patients with mantle cell lymphoma (MCL).

Rekha Rao, PhD, discusses targeting p97 in mantle cell lymphoma.

Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of bendamustine plus cytarabine as treatment for patients with mantle cell lymphoma.

The combination of rituximab, bendamustine, and low-dose cytarabine is an effective induction regimen for elderly patients with mantle cell lymphoma.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of bendamustine and rituximab (Rituxan; BR) plus bortezomib (Velcade) as a potential treatment for patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses recent therapeutic advancements in the field of mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses maintenance strategies for treating patients with mantle cell lymphoma.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy reported with ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the impact lenalidomide (Revlimid) has had on the treatment paradigm of mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the takeaways for community oncologists in the field of mantle cell lymphoma (MCL).

Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses why the Syk inhibitor entospletinib demonstrates efficacy in patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the history of bortezomib as a treatment for patients with mantle cell lymphoma.

Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses the mechanism of action with entospletinib (GS-9973) and its potential as a treatment for patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses phase III results of a study exploring rituximab as maintenance therapy after autologous stem cell transplantation in younger patients with mantle cell lymphoma.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses how the treatment landscape of mantle cell lymphoma is evolving.

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer, discusses highlights from the 2016 ASH Annual Meeting focused on the area of mantle cell lymphoma (MCL).

Younger patients with mantle cell lymphoma lived significantly longer and without disease progression or clinical events when they received rituximab maintenance therapy after stem cell transplantation, final results of a randomized trial showed.

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses personalized medicine in mantle cell lymphoma (MCL).

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses frontline lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).